Yes—Zepbound (tirzepatide) is the one GLP-1-based medicine FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. It is not a replacement for getting the right sleep-apnea assessment or for deciding with your clinician which combination of treatment, reduced-calorie eating and physical activity fits your situation.
The news is about one approved medicine for a defined group, not a blanket answer for everyone with snoring, poor sleep or daytime tiredness.
Disclosure: New Life Wellness Guide may publish wellness resources.
Are any GLP-1s approved for sleep apnea?
As of October 2026, the FDA has approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and increased physical activity. It is the first FDA-approved medication for this use.
The FDA based that decision on two randomized, placebo-controlled studies involving 469 adults without type 2 diabetes. One study included people using positive airway pressure (PAP), and the other included people unable or unwilling to use PAP. At 52 weeks, the tirzepatide groups had greater reductions in breathing events per hour and body weight than placebo.
That is useful news if weight and appetite are part of your bigger health picture. For a practical routine-oriented discussion, see Weight Loss and Appetite Control.
How do the real options compare?
| Option | What it addresses | Who it may fit | What to confirm |
|---|---|---|---|
| PAP therapy, including CPAP | Keeps the airway open during sleep. | People whose clinician recommends PAP after assessment. | Equipment, fitting, comfort, follow-up and plan coverage. |
| Zepbound (tirzepatide) | FDA-approved for moderate-to-severe OSA in adults with obesity, with reduced-calorie eating and more physical activity. | Adults who meet the approved indication and whose clinician considers it appropriate. | Benefits, side effects, package cost, coverage and follow-up testing. |
| Other GLP-1 medicines | Some research has examined the drug class and sleep-disordered breathing. | People discussing an existing prescription or another weight-management need with a clinician. | Whether the specific medicine has an OSA indication; semaglutide has not been evaluated in an OSA-specific randomized trial. |
| Everyday weight-management support | Meals and physical activity can support the reduced-calorie diet and activity approach used with the approved medicine, as the FDA describes. | Anyone building a sustainable routine with their care team. | A plan you can keep doing and how it fits alongside apnea care. |
PAP was the standard of care in one of the FDA’s pivotal studies. A clinician can help you compare a medicine, PAP, or both based on your test results, anatomy, weight goals and day-to-day comfort.
What does the GLP-1 research actually show?
A 2026 Sleep and Breathing meta-analysis pooled four randomized trials in adults with OSA and found that GLP-1 therapies were associated with fewer apnea-hypopnea events and greater weight loss than placebo. The authors also reported substantial variation among studies, background treatments and follow-up length, so the results are not a promise of the same outcome for every person.
The same review found a larger pooled change in apnea-hypopnea index with tirzepatide than with liraglutide. It also states that semaglutide has not been studied in randomized trials specifically targeting obstructive sleep apnea. That is why “GLP-1 for sleep apnea” is too broad a phrase: the approved product and the condition it is approved for matter.
What did the October 2026 retatrutide trials find?
The newest GLP-1 sleep apnea results are encouraging, including for people with type 2 diabetes, but retatrutide is still investigational and is not FDA-approved for any use. In two phase 3 trials published October 21, 2026, the NEJM trial found that weekly retatrutide plus lifestyle counseling lowered breathing events more than placebo over 80 weeks.
The trials included 243 adults without type 2 diabetes and 448 with it. Participants had moderate-to-severe OSA, a BMI of at least 27, and in-lab sleep studies; most started with severe OSA. Their average starting AHI was 58.6 events an hour without diabetes and 55.9 with diabetes. AHI is the average number of breathing pauses or shallow-breathing events per hour of sleep.
| Trial group | Change in AHI at 80 weeks | Weight change | Combined sleep result |
|---|---|---|---|
| Without type 2 diabetes | The two higher-dose groups fell by 34.3 and 31.7 events an hour, versus 9.9 with placebo. | 22.2% and 20.6%, versus 4.8% with placebo. | 51.6% in one higher-dose group reached either remission (AHI under 5) or mild OSA without excessive daytime sleepiness, versus 12.5% with placebo. |
| With type 2 diabetes | The two higher-dose groups fell by 24.7 and 25.4 events an hour, versus 10.3 with placebo. | 17.9% and 18.5%, versus 5.6% with placebo. | 39.5% in one higher-dose group reached that combined remission-or-mild-OSA result, versus 12.6% with placebo. |
The lower-dose retatrutide group also beat placebo on AHI. Sleep-related hypoxic burden fell about 63% to 75% in the higher-dose groups, compared with about 26% to 30% with placebo. The trial cannot yet answer whether those changes improve long-term heart outcomes.
Gastrointestinal effects, including diarrhea, nausea and constipation, were most common. Medscape’s report says serious adverse events occurred in 8% of retatrutide groups and 10% of placebo groups, with one adjudication-confirmed pancreatitis case. The trials were funded by Eli Lilly, which also participated in their design, conduct, analysis and manuscript preparation.
Will losing 20 pounds cure sleep apnea?
There is no fixed 20-pound rule in the FDA approval. Weight reduction can lower OSA severity for some people, but OSA involves more than weight alone. Your follow-up sleep assessment is what tells you and your clinician whether your breathing events have changed; it is not something a scale, a pillow or a social-media rule can settle.
Do not stop or change prescribed apnea treatment based on weight change alone. Bring your current PAP use, symptoms and weight trend to your next appointment so the plan can be reviewed together.
What should happen before a CPAP change?
A lower number on the scale is a reason to discuss follow-up, not proof that sleep apnea is gone. A sleep specialist quoted by Medscape recommends repeat sleep testing after significant weight loss because residual mild OSA can still disrupt sleep.
Keep using CPAP unless your clinician directs a change after reassessment. A home sleep test may be a reasonable part of that decision; the point is to measure your current breathing before deciding whether CPAP still belongs in your plan.
If appetite and weight are part of that plan, see Weight Loss and Appetite Control.
What about the Japanese trick, pillow trick, 3 rule, food and drinks?
These search phrases can make sleep apnea sound like a problem with one household item or one bedtime hack. They are not a substitute for assessing repeated breathing pauses during sleep. A pillow may affect comfort, and food or drink choices may affect how you feel at night, but neither is the FDA-approved treatment described in the Zepbound decision.
For ordinary sleep comfort, the NHS notes that large meals close to bedtime, caffeine and alcohol can disrupt sleep, while a warm milky drink or herbal tea may be an option for some people. That is general sleep guidance, not a treatment for airway blockage. If you are exploring comfort practices separately, read do far infrared saunas improve sleep quality.
Will insurance cover Zepbound for sleep apnea?
WebMD (reviewed June 2025) reports that insurers may require prior authorization, a diagnosis of both sleep apnea and obesity, and sometimes a trial of CPAP first; coverage depends on the specific plan, so ask your plan and prescriber.
When you ask, use the full approved indication: moderate-to-severe obstructive sleep apnea in an adult with obesity. Ask whether the plan needs your sleep-study result, clinician notes, a prior-authorization request or evidence of other treatment steps.
Where does retatrutide leave your choices today?
Retatrutide is a research result, not a current treatment choice. A vial marketed online as “research-use retatrutide” is not the trial drug. There is also no head-to-head trial showing whether retatrutide has an advantage over tirzepatide.
Your real options today are a sleep study to assess suspected or changing OSA; CPAP or another PAP approach; an oral appliance when a clinician considers one suitable; and, for adults who meet the indication, an approved weight-loss medicine such as Zepbound through a prescriber. The FDA says Zepbound is approved for moderate-to-severe OSA in adults with obesity alongside reduced-calorie eating and increased physical activity.
Mounjaro and Zepbound contain tirzepatide, but it is Zepbound that has the FDA OSA indication. For questions about other GLP-1 formats, see Ozempic pill availability.
Before you decide
- Ask what your sleep study shows, including your apnea-hypopnea index.
- Ask whether you meet the FDA-approved Zepbound indication.
- Compare PAP, weight-management support and medication as parts of one plan rather than assuming one replaces the others.
- Ask about side effects, medication interactions, monitoring, package options, refund terms where relevant and your actual coverage before any order.
- Arrange follow-up so changes in symptoms or weight are assessed with your clinician.
By the New Life Wellness Guide Editorial Team